Search Medical Condition
Please enter condition
Please choose location
 

Kokkola, Finland Clinical Trials

A listing of Kokkola, Finland clinical trials actively recruiting patients volunteers.

RESULTS

Found (8) clinical trials

The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)

Coronary bifurcation lesions with stenosis in a large side branch may require complex stent implantation techniques with an elevated risk of suboptimal treatment results. Intra vascular optical coherence tomography (OCT) enables improved procedural control of correctable factors and may lead to optimized implantation results. It is unknown if routine, systematic ...

Phase N/A

0.0 miles

Learn More »

Efficacy Safety and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Adults

This randomized, observer-blind, placebo-controlled multicenter, Phase 3 study will be conducted at multiple sites. The composition of the Quadrivalent VLP Influenza Vaccine to be used in this study includes a mix of recombinant H1, H3, and two B hemagglutinin proteins expressed as VLPs for the 2017-2018 influenza virus strains. Approximately ...

Phase

0.0 miles

Learn More »

Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix During Pregnancy or Immediately Post-delivery

The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' Infanrix hexa, given in the primary vaccination schedule to infants born to pregnant women who participated in study 116945 [DTPA (BOOSTRIX)-047]. This study will help us evaluate if the presence of transplacentally transferred maternal antibodies ...

Phase

2.35 miles

Learn More »

Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.

Since the HZ/su vaccine has not yet been licensed and marketed, this study is being conducted to enable potentially eligible subjects who previously received placebo in ZOSTER-006 (NCT01165177) or ZOSTER-022 (NCT01165229) to receive the HZ/su vaccine. Study ZOSTER-056 is an open-label, multi-centric and single arm study to cross-vaccinate and collect ...

Phase

2.35 miles

Learn More »

Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563) in Healthy Infants Starting at Age 6-12 Weeks

- Experimental design: Phase IIIA, observer-blind, randomised (1:1:1:1), controlled, multi-centric, with four parallel groups and a staggered enrolment (Part A and Part B). - Duration of the study: The intended duration of the study, per subject, will be approximately 7-8 months including the 6 months of extended safety follow-up period ...

Phase

2.35 miles

Learn More »

Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection

The study is designed as an event-driven group sequential protocol with 4 interim analyses at defined information milestones and a final analysis when a specific number of clinical endpoints are reached. Subjects will be randomly assigned to receive either the candidate vaccine or a placebo that will be administered in ...

Phase

2.35 miles

Learn More »

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

This study is examining safety and immunogenicity of 2 doses of Trumenba administered on a 0-,6- month schedule. This trial is also studyng safety and immunogenicity of a meningococcal pentavalent vaccine.

Phase

2.35 miles

Learn More »

Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of QIVc in Subjects 2 to 18 Years of Age

The randomized, observer-blind non-influenza comparator controlled study is intended to demonstrate the efficacy, immunogenicity, safety and tolerability of Seqirus' cell-based inactivated quadrivalent vaccine (QIVc) in subjects ≥2 years to <18 years of age

Phase

2.35 miles

Learn More »